<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00678483</url>
  </required_header>
  <id_info>
    <org_study_id>EFC10139</org_study_id>
    <secondary_id>EudraCT : 2007-002492-14</secondary_id>
    <nct_id>NCT00678483</nct_id>
  </id_info>
  <brief_title>Long-Term Effect of 10 mg Versus 20 mg Rimonabant in Overweight or Obese Patients</brief_title>
  <acronym>MODERATO</acronym>
  <official_title>A Randomized, Double-Blind, Parallel-Group, Multicenter, Multinational Study to Assess the Long-Term Effect, Over 1 Year, of Rimonabant 10 mg in Comparison With Rimonabant 20 mg After an Initial Treatment Period of 6 Months With Rimonabant 20 mg in Overweight or Obese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess, over a period of 12 months, the effect on
      weight loss and weight maintenance of rimonabant 10 mg in comparison with rimonabant 20 mg in
      overweight/obese patients after an initial treatment period of 6 months with rimonabant 20
      mg.

      Secondary objectives are to assess the effect of rimonabant over a period of 12 months on
      waist circumference, high-density lipoprotein (HDL)-Cholesterol and triglycerides (TG),
      fasting plasma glucose (FPG), fasting insulin and to evaluate the long-term safety and
      tolerability of rimonabant 10 mg and 20 mg over a period of 12 months after randomization in
      overweight/obese patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Company decision taken in light of demands by certain national health authorities
  </why_stopped>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the change in weight from baseline to 12 months</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: - Absolute change in waist circumference from baseline - Relative change in HDL-Cholesterol and in Triglycerides from baseline - Absolute change in Fasting Plasma Glucose from baseline</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety : Vital signs, adverse events, laboratory tests</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">331</enrollment>
  <condition>Obesity</condition>
  <condition>Weight Loss</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rimonabant (SR141716)</intervention_name>
    <description>once daily</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass index (BMI) of at least 30 kg/m² or BMI &gt;27 kg/m² with associated risk
             factors such as type 2 diabetes or dyslipidemia

        Exclusion Criteria:

          -  Weight loss &gt; 5 kg within 3 months prior to screening Visit.

          -  Presence of any clinically significant endocrine disease including the presence of
             type 1 diabetes

          -  Presence of any severe medical or psychological condition that, in the opinion of the
             investigator, would compromise the patient's safe participation including uncontrolled
             serious psychiatric illness such a major depression within the last 2 years, and
             history of other severe psychiatric disorders

          -  Previous participation in a clinical study with rimonabant

          -  Administration of other investigational drugs, anti-obesity drugs or other drugs for
             weight reduction

          -  Pregnancy and absence of effective contraceptive method for females of childbearing
             potential

          -  Exenatide

          -  Insulin therapy

          -  Recent change or need for change in the oral antidiabetic treatment

          -  Recent change or need for change in the lipid lowering treatment

          -  Presence of severe renal or hepatic impairment

        The above information is not intented to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ICD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi- Aventis Administrative Office</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
    <country>Finland</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2008</study_first_submitted>
  <study_first_submitted_qc>May 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2008</study_first_posted>
  <last_update_submitted>June 16, 2009</last_update_submitted>
  <last_update_submitted_qc>June 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>ICD</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>Cholesterol</keyword>
  <keyword>HDL</keyword>
  <keyword>triglycerides</keyword>
  <keyword>insulin</keyword>
  <keyword>blood glucose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rimonabant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

